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Diabetes mellitus (DM) is a chronic metabolic disorder commonly characterized by high blood glucose levels, resulting from defects
in insulin production or insulin resistance, or both. DM is a leading cause of mortality and morbidity worldwide, with diabetic
cardiomyopathy as one of its main complications. It is well established that cardiovascular complications are common in both
types of diabetes. Electrical and mechanical problems, resulting in cardiac contractile dysfunction, are considered as the major
complications present in diabetic hearts. Inevitably, disturbances in the mechanism(s) of Ca2+ signaling in diabetes have
implications for cardiac myocyte contraction. Over the last decade, signiﬁcant progress has been made in outlining the
mechanisms responsible for the diminished cardiac contractile function in diabetes using diﬀerent animal models of type I
diabetes mellitus (TIDM) and type II diabetes mellitus (TIIDM). The aim of this review is to evaluate our current understanding
of the disturbances of Ca2+ transport and the role of main cardiac proteins involved in Ca2+ homeostasis in the diabetic rat
ventricular cardiomyocytes. Exploring the molecular mechanism(s) of altered Ca2+ signaling in diabetes will provide an insight
for the identiﬁcation of novel therapeutic approaches to improve the heart function in diabetic patients.

1. Introduction
Diabetes mellitus (DM) is a chronic metabolic disorder commonly characterized by abnormally high blood glucose levels,
resulting from defects in insulin production or insulin resistance, or both. Over the years, prevalence of diabetes has
increased globally, and it is classiﬁed as one of the leading
causes of mortality and morbidity. TIDM is characterized
by decreased insulin secretion due to the damage in β cells
of the pancreas [1, 2]. In contrast, TIIDM is characterized
by decreased peripheral resistance to insulin, resulting in
reduced insulin sensitivity to the skeletal muscles, adipose tissues, and liver [1, 3]. Hyperglycemia plays an important role
in the onset and development of diabetes complications,
mainly by generating reactive oxygen species (ROS) which
causes lipid peroxidation and membrane damage. Furthermore, hyperglycemia results in excessive nonenzymatic glycation of proteins and formation of advanced glycation end
products (AGE). The glycation modiﬁcations can further
deteriorate the pathology of diabetes [4, 5].

Diabetic cardiomyopathy is one of the complications in
DM. Electrical and mechanical problems, resulting in cardiac
contractile dysfunction, are the major complications present
in diabetic hearts. Clinical and preclinical studies have demonstrated a variety of diastolic and systolic dysfunctions in
diabetic patients with the severity of abnormalities depending on the patients’ age and duration of diabetes. Cardiac
contractility is controlled through the precise interplay
between several cellular Ca2+ transport protein complexes.
During the excitation-contraction coupling process, the
arrival of an action potential (AP) at a cardiac myocyte depolarizes the cell membrane leading to the opening of L-type
Ca2+ channels and the inﬂux of small amounts of Ca2+. This
inﬂux of Ca2+ triggers a much larger Ca2+ release from the
sarcoplasmic reticulum (SR) via the ryanodine receptors
(RyRs) and a transient increase in intracellular Ca2+ (Ca2+
transient). Ca2+ binds to troponin C and initiates and regulates the process of myocyte contraction. Myocyte relaxation
takes place by the Ca2+ removal from the cytosol via main
pathways including the uptake of Ca2+ into the SR through
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the SR Ca2+-ATPase (SERCA pump), transport outside the
cell mainly via the Na+/Ca2+ exchanger (NCX), in addition
to the plasma membrane Ca2+-ATPase (PMCA) [6]. A
fourth pathway of the Ca2+ extrusion potentially involves
mitochondria which are equipped with an eﬃcient machinery for Ca2+ transport and are capable of storing large
amounts of Ca2+ [7–10].
Disturbances in the mechanism(s) of Ca2+ signaling predictably have implications for cardiac myocyte contraction. It
is well established that cardiovascular complications are
common in both types of diabetes. Over the last decade, signiﬁcant progress has been made in outlining the mechanisms
responsible for the diminished cardiac contractile function in
diabetes using diﬀerent animal models of TIDM and TIIDM.
The aim of this review is to evaluate our current understanding of the disturbances of Ca2+ transport and the role of main
cardiac proteins involved in Ca2+ homeostasis in the diabetic
rat ventricular cardiomyocytes. Exploring the molecular
mechanism(s) of altered Ca2+ signaling in diabetes will provide an insight for the identiﬁcation of novel therapeutic
approaches to improve heart function in diabetic patients.

2. L-Type Ca2+ Channel
The cardiac voltage-gated L-type Ca2+ channel, Cav1.2, is the
main pathway for the Ca2+ entry into the cardiac cell. The
fully functional Cav1.2 channel is a heterotetrameric polypeptide complex containing the pore-forming Cavα1c subunit, in addition to the accessory subunits Cavβ, Cavα2δ,
and Cavγ [11]. The pore-forming Cavα1c subunit contains
the main biophysical and pharmacological properties of the
channel and plays a critical role in excitation–contraction
coupling. Entry of Ca2+ through Cav1.2 channels shapes the
plateau phase of the ventricular action potential and determines the action potential duration. In addition to the ion
channel pore, the Cavα1c subunit also consists of the voltage
sensor, selectivity ﬁlter, and the determinants for the binding
of drugs and toxins. The current through the Cavα1c subunit
is modulated by the interactions with the accessory subunits
that are tightly bound to the Cavα1c subunit. All of these
accessory subunits play important roles in the regulation of
both the biophysical properties and traﬃcking of L-type
Ca2+ channels [11–13].
Compared to the surface sarcolemma, L-type Ca2+ channels are more localized in the T-tubule [13]. Within the Ttubule, most of L-type Ca2+ channels are concentrated in a
speciﬁc region called dyad. Each dyad consists of clusters of
L-Type Ca2+ channels on the sarcolemma closely opposed
to clusters of RyRs on the SR membrane [6]. The two molecules are separated by a very limited space (10–15 nm) that
enables a few Ca2+ ions to pass through the L-type Ca2+
channels and activate the RyRs. Such distribution forms the
structural basis of excitation–contraction coupling [6, 13].
The L-type Ca2+channel activity is positively regulated by
protein kinase A (PKA) phosphorylation. β-Adrenergic
stimulation and the resulting PKA-mediated phosphorylation of key residues cause an approximately threefold surge
in the L-type Ca2+ channel activity as a result of an increase
in the channel open probability (Po ) [14, 15]. The L-type cur-
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rent inactivates via two distinct mechanisms: a voltagedependent inactivation, that is regulated by CaVβ, and a
Ca2+-dependent inactivation, that is regulated by calmodulin
(CaM). Both processes are thought to limit the amount of
Ca2+ inﬂux during the AP [16].
2.1. L-Type Ca2+ Channel in Type I Diabetes Mellitus. Various animal models are used to study TIDM. Deﬁciency in
insulin production is achieved by a variety of mechanisms,
ranging from chemical induction of beta cell damage (STZinduced and alloxan-induced diabetes) [17] to genetic induction (e.g., AKITA mice) [18]. Previous studies in TIDM animal models have variously reported either no change [19–22]
or reduction in the L-type Ca2+ current [20, 23–28] in ventricular myocytes isolated from the STZ-induced diabetic
rat. For example, Chattou et al. 1999 found that, in rat diabetic myocytes, the density of the Ca2+ current was signiﬁcantly reduced by TIDM in the range of test potentials
between -10 and +50 mV. In addition, the fast time constant
of the Ca2+ current inactivation was signiﬁcantly higher in
diabetic compared to normal myocytes which indicates that
SR Ca2+ release-induced inactivation is delayed in TIDM.
The decrease in the L-type Ca2+ current, which is the trigger
for Ca2+-induced Ca2+ release (CICR) from SR, may explain
the signiﬁcantly lowered peak systolic intracellular Ca2+ in
diabetic ventricular myocytes [20, 23–26]. Supporting this
ﬁnding, Bracken et al. (2006) have shown that TIDM induced
voltage-dependent decrease in contraction that was associated with the reduced L-type Ca2+ channel activity [28]. In
cardiac myocytes of type 1 diabetic Akita Mice, decreased
contractility was associated with reduced PI 3-kinase signaling and reduced cell surface expression of L-type Ca2+ channels. This change results in the decrease of the L-type Ca2+
current density that was reversed to control levels by insulin
treatment and intracellular infusion of PI 3,4,5-trisphosphate
[PI(3,4,5)P3] [27].
In contrast to the above ﬁndings, a recent study conducted by Smail et al. (2016) has shown that the L-type
Ca2+ channel activation, inactivation, and recovery from
inactivation were not signiﬁcantly altered in epicardial and
endocardial myocytes from STZ-treated rats [19].
2.2. L-Type Ca2+ Channel in Type II Diabetes Mellitus. In
db/db obese type II diabetic mice, the depressed cardiac function was associated with reduction in the membrane permeability to Ca2+. Although the macroscopic L-type Ca2+
current was reduced in db/db cardiomyocytes, the single
Ca2+ channel activity was similar, suggesting that diabetic
myocytes express fewer functional Ca2+ channels [29]. The
diminished T-tubular density was also observed in db/db
mice in cardiomyocytes from mice with type II diabetes
(db/db) [30]. Zucker diabetic fatty rat is a genetic model in
which the male homozygous (FA/FA) animals develop obesity and TIIDM. In this model, earlier study has shown that
the L-type Ca2+ current was reduced, and inactivation was
prolonged over a range of test potentials in diabetic ventricular myocytes. Upregulation of the gene encoding the α1 subunit of the Cav1.2 ion channel (Cacna1c) may provide an
early compensatory mechanism for the reduced density and
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prolonged inactivation of the L-type Ca2+ current demonstrated in myocytes from Zucker diabetic fatty rat compared
to their respective controls [31]. In contrast to these ﬁndings,
recent studies on the Goto–Kakizaki (GK) rat, a nonobese
genetic model of TIIDM, have shown no change in the Ltype Ca2+ channel activity in ventricular myocytes [32, 33].
Eﬀects of TIDM and TIIDM on the L-type Ca2+ channel
are summarized in Table 1.

3. The Ryanodine Receptor Type 2
Ryanodine receptor type 2 (RyR2) is a member of the RyR
family. It is a macromolecular homotetrameric protein complex that regulates Ca2+ release from the SR during the process of excitation-contraction coupling in the heart.
Sarcolemmal depolarization results in the entry of a small
amount of Ca2+ to the cardiac cell. This inﬂux of Ca2+ stimulates a large release of Ca2+ from the SR via RyR2 resulting
in a transient rise of cytosolic Ca2+. In fact, activation of single RyR2 cluster (8–100 channels) results in an increase in the
concentration of cytosolic Ca2+, known as a Ca2+ spark [34].
The summation of all Ca2+ sparks produced by activated
RyR2 clusters throughout the cardiomyocyte leads to a
Ca2+ transient that causes cardiac muscle contraction [35].
Recently, super-resolution imaging methods have provided
an estimate for the number of RyRs in each cluster (dyad)
from ≈14 in peripheral couplings to ≈100 in intracellular
sites [34, 36]. A number of accessory proteins are associated
with RyR2 and modulate its function including (1) the Ca2+
binding protein calmodulin which directly binds with and
regulates RyR2 channels; (2) auxilliary proteins, calsequestrin, triadin, and junctin, which form the luminal Ca2+ sensor
of RyR2 within the SR [37–39]; and (3) FK506 binding proteins (FKBP12 and FKBP12.6), which are believed to interact
with RyR2 and stabilize the channel, preventing spontaneous
Ca2+ release and SR Ca2+ leak [40]. In addition, the protein
complex interacts with a number of enzymes including
PKA, Ca2+/calmodulin-dependent protein kinase II (CaMK
II), and phosphatases 1, 2A, and 2B that reversibly modulate
the receptor phosphorylation state [41, 42].
3.1. The Ryanodine Receptor in Type I Diabetes Mellitus. To
date, the molecular mechanism underlying RyR2 dysregulation during chronic diabetes is incompletely understood.
Alteration in the sensitivity of RyR2 to the Ca2+ activation,
oxidation of RyR2 by ROS and/or reactive carbonyl species
[43–46], and functional uncoupling of RyR2 from L-type
Ca2+ channels on the T-tubule membranes could be partly
responsible for the dyssynchronous Ca2+ release from SR in
diabetes [47].
In STZ-injected rats, earlier study conducted by Yu et al.
(1994) reported a decrease in 3H-labeled ryanodine binding
sites in diabetic myocardium, suggesting decreased density
of the RyR protein [48]. Supporting this ﬁnding, Teshima
et al. (2000) reported a decrease in the expression of RyR2
mRNA, 12 weeks after the STZ injection in the diabetic rat
heart [22]. A more recent study also showed a signiﬁcant
decrease in the expression of RyR2 in 4-, 8-, and 12-week
STZ-treated diabetic groups [49]. Together, the decreased
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density of RyR2 in the STZ rat heart can be explained by corresponding decrease in the mRNA expression.
It is well known that metabolic changes associated with
diabetes increase the production of ROS. As the RyR structure is rich in free thiol groups, it is highly subject to oxidative
stress, changing its tertiary structure and altering its sensitivity to Ca2+ [2, 50]. In an earlier study in 7-week sedentary
type-1 diabetic rats, Ca2+ spark frequency was threefold
higher, and evoked Ca2+ release was dyssynchronous with
diastolic Ca2+ release. Although the steady state of the RyR2
protein (the state under which there is a continuous presence
of critical Ca2+ to maintain the channel in its open state) was
not altered, its response to Ca2+ was changed [51]. Yaras et al.
(2005), however, found that in STZ-treated diabetic rats,
Ca2+ transients exhibit signiﬁcantly reduced amplitude and
prolonged time courses, as well as depressed Ca2+ loading
of SR. Spatiotemporal properties of the Ca2+ sparks were also
signiﬁcantly altered. Furthermore, protein levels of RyR2
were depleted [52]. Supporting these ﬁndings, the decreased
expression of RyR2 receptors was reported earlier using the
quantitative immunoblot technique. As a result, the
decreased RyR function was responsible for the slow release
of Ca2+ from SR and prolonged time to peak Ca2+ transients
observed in diabetic rat myocytes [21]. Similar ﬁndings were
also reported by other groups [51, 53, 54].
Alterations in the sensitivity of RyR2 to the Ca2+ activation could result from increased phosphorylation by PKA
and CaMKII [43, 55, 56]. PKA was found to phosphorylate
two sites of RyR2, primarily Ser2808 (in human and rodents)
or Ser2809 (in rabbit) and Ser2030 (or Ser2031 in rabbit).
CAMKII also phosphorylates the Ser2808 site, in addition
to the Ser2814 (Ser2815 in rabbit) site [57]. The functional
role of PKA and CaMKII-mediated phosphorylation of
RyR2 has been implicated in many heart diseases, including
heart failure [51, 53, 58]. For example, Marx et al. (2000)
showed that PKA phosphorylation regulates the binding of
FKBP12.6 to RyR2. PKA phosphorylation dissociates the regulatory subunit FKBP12.6 from the channel, resulting in the
altered channel function which is manifested as increased probability of open state (Po), increased sensitivity to the Ca2+induced activation, and destabilization of the channel [58].
In diabetic rat ventricular cardiomyocytes, Shao et al.
(2009) showed that the RyR displayed about 1.5-fold increase
in phosphorylation at Ser 2808 and Ser 2814 residues 7 weeks
after STZ injection [51]. Interestingly, the PKA activity was
reduced by 75%, but the CaMKII activity was increased by
50% [51]. Conversely, Yaras et al. (2005) reported that
PKA-dependent phosphorylation of RyR2 was partly responsible for impaired intracellular Ca2+ signaling, as well as
decreased SR Ca2+ load [52]. However, the role of CaMKII
in phosphorylation of RyR2 and disturbance of Ca2+ signaling has been reported in STZ-diabetic rats [59] and db/db
mice [30]. Interestingly, Tian et al. (2011) stated that the
change in the RyR2 function observed in single channel
recordings was independent of phosphorylation at either
S2808 or S2814 sites. Instead, the increase in open channel
probability (Po) and reduction in conductance were attributed to the increased responsiveness to cytoplasmic activators including Ca2+ [60].
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Table 1: Eﬀect of DM on the L-type Ca2+ channel.

TIDM

Eﬀect
References
Reduced L-type Ca2+ current in STZ-treated rat
Hamouda et al. 2015 [23]; Wang et al. 1995 [24]; Chattou et al. 1999
ventricular myocytes
[26]; Bracken et al. 2006 [28]; Woodall et al. 2004 [25]
2+
Reduced L-type Ca current in Akita(ins2) mice
Lu et al. 2007 [27]
No signiﬁcant change in the L-type Ca2+ current in STZ- Smail et al. 2016 [19]; Lacombe et al. 2007 [20]; Choi et al. 2002 [21];
treated rat ventricular myocytes
Teshima et al. 2000 [22]

TIIDM

Eﬀect
Reduced number of L-type Ca2+ channels in sarcolemma
in db/db mice
Reduced density of T-tubular in db/db mice
No change in L-type Ca2+ channels in Goto-Kakizaki rats
Upregulation of the gene encoding Cav1.2 ion channel
(Cacna1c)

3.2. The Ryanodine Receptor in Type II Diabetes Mellitus. In
the prediabetic animal model of metabolic syndrome, the
integrity of RyR2 was assessed by Ser 2809 phosphorylation,
in addition to the receptor’s ability to bind [3H]ryanodine.
RyR2 phosphorylation at Ser 2809 was signiﬁcantly elevated
in the right and left ventricles from high-fat-fed dogs compared to normal controls. This hyperphosphorylation was
associated with a decrease in RyR2 binding aﬃnity in the
right and left ventricles. However, there was no change in
the level of expression of RyR2 [61]. In a more recent study
on rats with metabolic syndrome, induced by a 16-week
high-sucrose diet, cardiomyocytes exhibited altered Ca2+ signaling that was partly attributed to increased phosphorylation and altered RyR2 function [62]. Gaber et al. (2014)
found that, in the GK rat model, changes in ventricular cardiomyocyte shortening and Ca2+ signaling were associated
with a decrease in RyR2 mRNA levels [63]. Supporting this
ﬁnding, prolonged SR Ca2 + release and associated reduced
RyR2 expression and increased phosphorylation were
reported in the right atrial myocardium of TIIDM patients
[64].
Diabetes and obesity are associated with an increased risk
of arrhythmia and sudden cardiac death that could be partly
attributed to abnormal lipid accumulation. Recently, the
transgenic mouse model of cardiac lipid overload, with the
cardiac-speciﬁc overexpression of peroxisome proliferatoractivated receptor gamma (PPAR-γ), was used to study the
change in Ca2+ handling [65, 66]. The PPAR-γ overexpression was found to perturb the intracellular Ca2+ homeostasis
in cardiomyocytes leading to ventricular arrhythmias and
cardiac sudden death in animals. The results of a recent study
conducted by Joseph et al. (2016) showed that PPAR-γ cardiomyocytes had more frequent triggered activity, increased
sparks, and SR Ca2+ leak. This was attributed to the signiﬁcant increase in RyR2 oxidation [65]. Other studies have also
reported that in vitro oxidation of RyR2 increases the channel response to cytoplasmic Ca2+ concentration and favors
Ca2+ release in isolated cardiomyocytes, generating Ca2+
waves and arrhythmias [67, 68].
In mice fed with a high-fat diet (HFD), more frequent
occurrence of arrhythmic episodes was associated with an
enhanced response of single RyR2 channels to cytoplasmic

References
Pereira et al. 2006 [29]
Stølen et al. 2009 [30]
Salem et al. 2013 [32]; Al Kury et al. 2018 [33]
Howarth et al. 2011 [31]

Ca2+. At the molecular level, RyR2 channels from HFD-fed
mice had substantially fewer free thiol residues, suggesting
that redox modiﬁcations were responsible for the higher
activity of RyR2 [69]. Eﬀects of TIDM and TIIDM on RyR2
are summarized in Table 2.

4. The Sarcoplasmic Reticulum Ca2+-ATPase
SERCA pump plays a predominant role in cardiac excitation–contraction coupling and cardiac contractility. This
pump is encoded by a family of three genes, SERCA1, 2,
and 3, which are spliced in several isoforms. To date, more
than 10 diﬀerent SERCA isoforms have been identiﬁed at
the protein level. In the cardiac tissue, SERCA2a is the predominant form which is responsible for facilitating the storage of Ca2+ in the SR. The function of the SERCA2a pump is
modulated by the endogenous molecules phospholamban
(PLB), sarcolipin (SLN), and by direct phosphorylation
through CaMK II. In the dephosphorylated form, PLB
inhibits SERCA2a, while PKA-dependent phosphorylation
of the phosphoresidue serine-16 or Ca2+/calmodulin-dependent phosphorylation of threonine-17 reverses this inhibition
[70, 71]. SERCA2a is also under the control of CaMK II,
which has been shown to phosphorylate SERCA2a on residue
serine-38 and enhance and Ca2+-reuptake into the SR [72].
These eﬀects that are mediated through phosphorylation
result in an overall increased SR Ca2+-load and enhanced
contractility.
4.1. The Sarcoplasmic Reticulum Ca2+-ATPase in Type I
Diabetes Mellitus. Because SERCA2 plays a major role in
muscle contraction, various investigations have focused on
understanding its role in cardiac disease. Many studies have
reported that the SERCA2a expression and activity were
decreased in a number of pathophysiological conditions
including diabetes [73]. In TIDM, decreased activity of SERCA2a was associated with decreased level of mRNA levels or
expression of protein, increased formation of ROS, change in
the expression of PLB, and increased posttranslational modiﬁcation such as increased carbonylation, glycation, and OGlcNAcylation (Table 3). For example, in the STZ-induced
diabetic rat heart, the expression of SERCA2a mRNA was
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Table 2: Eﬀect of DM on ryanodine receptor type 2.

TIDM

Eﬀect
Decrease in 3H-labeled ryanodine binding sites, decrease in the mRNA
expression
Hyperphosphorylation of RyR2
Hyperphosphorylation of RyR2 due to both high phosphorylation levels of
both PKA and CaMKII
AGEs on RyR2, disulﬁde bond formation on RyR2, oxidation of RyR2 by
reactive oxygen species (ROS), and/or reactive carbonyl species
Slow release of Ca2+ from SR and prolonged time to peak Ca2+ transients

TIIDM

References
Yu et al. 1994 [48]; Teshima et al. 2000 [22]; Choi et al.
2002 [21]; Zhao et al. 2014 [49]
Yaras et al. 2005 [52]; Shao et al. 2007 [54]; Shao et al.
2009 [51]
Tuncay et al. 2014 [53]; Netticadan et al. 2001 [59]
Bidasee et al. 2003a [2]; Bidasee et al. 2003b [102];
Shao et al. 2012 [46]
Choi et al. 2002 [21]

Eﬀect
References
Decrease in RyR2 mRNA levels in the GK model
Gaber et al. 2014 [62]
Decrease in [3H]ryanodine binding aﬃnity in the right and left ventricle
Dincer et al. 2006 [60]
Increase in RyR2 phosphorylation at Ser 2808/Ser 2809
Dincer et al. 2006 [60]; Okatan et al. 2016 [61]
Increased oxidation of RyR2, decreased S-nitrosylation, and diastolic Ca2+ Oda et al. 2015 [66]; Gonzalez et al. 2007 [67]; Joseph
leak; increased activity in PPAR-γ overexpressed mice with high lipid; and et al. 2016 [64]; Xie et al. 2016 [65]; Sánchez et al. 2018
[68]
increased RyR2 activity due to redox modiﬁcation in HFD-fed mice

signiﬁcantly reduced 3 weeks after the STZ injection [22].
Kim et al. (2001) found that the maximal Ca2+ uptake and
the aﬃnity of SERCA2a for Ca2+ were decreased while the
exogenous phosphorylation level of PLB was increased in
STZ-induced diabetic rat SR. Levels of both mRNA and protein of PLB were signiﬁcantly increased in the diabetic hearts,
whereas those of SERCA2a were signiﬁcantly decreased.
Consequently, the relative PLB/Ca2+-ATPase ratio was 1.88
in the diabetic hearts, and these changes were correlated with
changes in the rates of SR Ca2+ uptake [74]. Choi et al. (2002)
also found that the depression in the SR function was associated with decreased SERCA2a and increased nonphosphorylated PLB proteins [21]. Supporting these ﬁndings, Bidasee
et al. (2004) found that the hearts of 8-week STZ-treated animals expressed lower levels of the SERCA2a protein and
higher levels of monomeric unphosphorylated PLB [75].
Decreased function of SERCA2a was also reported in other
studies including studies on the alloxan model of TIDM
[20, 76, 77].
Oxygen-derived free radicals have been reported to damage SERCA, leading to cellular Ca2+ overload. For example,
earlier study by Okabe et al. (1983) showed that a decrease
in Ca2+ uptake occurs in isolated SR after exposure to xanthine/xanthine oxidase, an enzymatic system capable of generating superoxide radicals [78]. Zu et al. (1997) found that
hydroxyl radical inhibits the SERCA2a function by directly
attacking the ATP binding site [79]. A more recent study
by Ying et al. (2008) showed that exposure of cardiac SR
membranes directly to peroxynitrite reduces the SERCA2a
activity by oxidizing Cysteine 674, as well as interfering with
the ATP binding site [80].
4.2. The Sarcoplasmic Reticulum Ca2+-ATPase in Type II
Diabetes Mellitus. Previous studies in TIIDM animal models
have variously reported either no change, decreased or
increased expression of SERCA2a. Although Stølen et al.
(2009) reported no change in the SERCA2a expression in
the db/db mouse, the decreased activity of SERCA2a was

attributed to the increased PLB expression [30]. Similarly,
in ventricular myocytes isolated from adult rats fed on
sucrose for 9-12 weeks, shortening/relengthening were signiﬁcantly shorter compared to starch- (ST-) fed controls.
Although the SERCA2a expression was unaltered, the inhibition was associated with decreased SR Ca2+ uptake and
increased PLB phosphorylation [81].
In contrast to the above ﬁndings, both a decrease and an
increase in the SERCA2a expression were observed in Zucker
Diabetic Fatty rat, an early TIIDM model. While Young et al.
(2002) reported a decrease in the SERCA2a expression and
cardiac contractility [82], a more recent study conducted by
Fredersdorf et al. (2012) showed that the SERCA2a expression is upregulated, whereas the expression of PLB mRNA
was reduced. The changes were associated with a signiﬁcant
increase in SR Ca2+ uptake. Interestingly, the SERCA2a
expression and SERCA/PLB ratio in diabetic animals were
further increased by insulin treatment. From a pathophysiological point of view, insulin-induced upregulation of SERCA2a could be regarded as a feedback mechanism in
handling the volume overload caused by high glucose levels
in the early phase of TIIDM, when insulin levels are high
[83]. Eﬀects of TIDM and TIIDM on SERCA2a are summarized in Table 3.

5. The Sodium-Calcium Exchanger
The NCX is an electrogenic transporter located at the plasma
membrane that catalyses the countertransport of Na+ and
Ca2+. To date, 4 isoforms have been identiﬁed for NCX,
namely, NCX1, NCX2, NCX3, and NCX4 [84]. The cardiac
isoform, NCX1, is organized into ten transmembrane segments (TMSs) with a large cytoplasmic loop between TMSs
5 and 6 that plays a regulatory role. Ion transport is associated with two regions of intramolecular similarity named α
repeats. They consist of TMSs 2–3 and TMSs 7–8 and their
connecting links [85]. NCX1 plays an important role in
Ca2+ homeostasis, typically by operating in forward mode
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Table 3: Eﬀect of DM on sarcoplasmic reticulum Ca2+-ATPase.

TIDM

Eﬀect
References
Decrease in mRNA level/protein expression of SERCA2a in STZTeshima et al. 2000 [22]; Choi et al. 2002 [21]; Kim et al.
treated diabetic rats
2001 [73]; Bidasee et al. 2004 [74]; Lacombe et al. 2007 [20]
Increase in mRNA level/protein expression of non-phosphorylated
Choi et al. 2002 [21]; Kim et al. 2001 [73]; Bidasee et al.
PLB in STZ-treated diabetic rats
2004 [74]
Decrease in the SERCA2a function in alloxan/STZ-treated diabetic Lopaschuk et al. 1983 [75]; Allo et al. 1991 [76]; Zhao et al.
rats
2014 [49]; Lacombe et al. 2007 [20]
Inhibition of SERCA2 by free radicals through the direct attack of
Xu et al. 1997 [78]; Ying et al. 2008 [79]
ATP-binding site
Downregulation through posttranslational modiﬁcations (glycation,
Bidasee et al. 2004 [74]
carbonylation, and O-GlcNAcylation)

TIIDM

Eﬀect
Decreased SR Ca2+ uptake, increased PLB phosphorylation, unaltered
SERCA2a expression in db/db mouse, and adult rats fed on sucrose
Decreased SERCA2a function, enhanced CaMKII-mediated
phosphorylation of PLB in Ob/Ob mice.
Decreased SERCA2a expression in Zucker Diabetic Fatty rat
Increased SERCA2a expression in Zucker Diabetic Fatty rat

to extrude one Ca2+ ion for 3 Na+ ions. The direction of Ca2+
transport reverses at membrane potentials near that of the
AP plateau, generating an inﬂux of Ca2+ into the cell [86].
NCX1 is regulated by intracellular Ca2+ [87], signaling lipid
phosphatidylinositol-4,5-bisphosphate (PIP2) [86], and free
radicals, as well as PKA and PKC [88, 89]. Alterations in
the ionic and electrical conditions that accompany cardiac
diseases promote reverse-mode of the NCX1 activity, leading
to Ca2+ overload and electrical dysfunction [86].
5.1. The Sodium-Calcium Exchanger in Type I Diabetes
Mellitus. Earlier studies have shown that the NCX current
density was reduced [20, 26, 90, 91], and current inactivation
was prolonged [26] in ventricular myocytes from STZinduced diabetic rat. These variations in amplitude and
kinetics of the current were accompanied with reduced
NCX mRNA [90] and reduced or unaltered NCX protein in
the STZ-induced diabetic rat heart [21, 92, 93]. In alloxaninjected rats, the NCX function was depressed 2 weeks after
diabetes induction [94]. Most recent data from our lab has
shown that the NCX current was signiﬁcantly smaller in
endocardial and epicardial ventricular cardiomyocytes compared to controls, 5-6 months after the induction of diabetes
with STZ [95].
Despite the fact that all of the abov-mentioned studies
have supported the decrease in NCX function in TIDM,
results from the Akita(ins2) TIDM model showed an
increase in the NCX expression as a compensatory mechanism in response to reduced contractility in the heart. Such
increase was protective against systolic failure [96].
5.2. The Sodium-Calcium Exchanger in Type II Diabetes
Mellitus. In mice with TIIDM (db/db), either no change or
increased activity of NCX1 was observed. For example, in
insulin-resistant sucrose-fed rats, the normal expression of
NCX1 was observed [81]. Similarly, Ricci et al. (2006) found
no change in the NCX current density in HFD mice [97].

References
Wold et al. 2005 [80]
Stølen et al. 2009 [30]
Young et al. 2002 [81]
Fredersdorf et al. 2012 [82]

However, Stølen et al. (2009) found an increased activity of
NCX1in TIIDM (db/db) [30]. An increased NCX1 gene
expression was observed in human with TIIDM and was
associated with comparable left ventricular hypertrophy
[98]. Eﬀects of TIDM and TIIDM on NCX1 are summarized
in Table 4.

6. Effect of Advanced Glycation Products on
Ca2+ Handling Proteins in Diabetes
Chronic hyperglycemia results in excessive formation of
advanced glycation end products (AGE). The glycation modiﬁcations can further deteriorate the pathology of diabetes [4,
5]. AGEs are a heterogenous group of molecules resulting
from the nonenzymatic glycation and oxidation of proteins
and lipids in the presence of reducing sugars. AGEs may alter
cellular function through crosslinking of cellular proteins or
by activating the AGE receptor (RAGE). In cardiomyocytes,
AGEs were shown to crosslink the domains of both the
RyR and SERCA2a [99]. Yan et al. (2014) showed that the
AGE/RAGE signal enhanced Ca2+ spark-mediated SR Ca2+
leak, which resulted in partial depletion of the SR Ca2+ content and consequently, decreased systolic Ca2+ transient.
Altogether, these eﬀects have contributed to contractile dysfunction reported in diabetic cardiomyopathy [100, 101].
As mentioned earlier, the RyR2 structure is rich in free
thiol groups and therefore, it is highly susceptible to oxidative
stress. Hegab et al. (2017) found that the AGE-induced activation of RAGE enhanced the activity of NADPH oxidase
and hence the production of ROS. This was accompanied
with activation of p38 kinase, nuclear translocation of NFκB, and subsequently induction of inducible nitric oxide synthase (iNOS) expression, leading to increased NO production. Elevation of ROS and NO was found to alter Ca2+
handling through S-nitrosylation of key proteins such as
SERCA2a, RyR2, and L-type Ca2+ channel [100, 102].
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Table 4: Eﬀect of DM on sodium-calcium exchanger.

TIDM

Eﬀect
Reduction NCX current density
Reduced in NCX mRNA
Reduced or unaltered NCX protein
Decreased NCX activity in alloxan-treated rats
Increased NCX expression in Akita(ins2) TIDM

TIIDM

Eﬀect
No change in the NCX expression and current density in
insulin-resistant sucrose-fed rats and HFD mice
Increased activity in the TIIDM model (db/db)
Increased NCX1 gene expression

The relationship between diabetes-induced decrease in the
RyR2 activity and the formation of AGE during chronic diabetes was also shown in other studies. Bidasee et al. (2003) have
shown that AGEs are formed on RyR2 during diabetes. RyR2
from 8-week STZ-induced diabetic rat hearts contained several noncrosslinking AGEs. Noticeably, decreased ability to
bind [3H]ryanodine and altered sensitivity to Ca2+ indicated
the loss of functional integrity of RyR2 from these hearts [2].
In fact, formation of AGEs on RyR2 was not the only contributor to RyR2 dysfunction. In a previous study conducted by
the same group on 6-week STZ-diabetic rat hearts, it was
shown that the dysfunction of RyR2 stems in part from
diabetes-induced increase in its disulﬁde bond content [103].
Furthermore, glycation of RyR2 was found to alter its gating
properties and was associated with increased SR Ca2+ leak, elevated mitochondrial Ca2+ content, and concomitant mitochondrial Ca2+ overload and damage [104] .
SERCA2a is susceptible to posttranslational modiﬁcations during diabetes. It has been identiﬁed as a prominent
target of glycative damage. Hearts from 8-week-old diabetic
rats treated with STZ showed several cytosolic SERCA2a
peptides, modiﬁed by single noncrosslinked and crosslinked
AGEs. Lysine residues within the actuator domain (A, cytoplasmic) and phosphorylation domain (P, cytoplasmic) were
crosslinked to arginine residues within the nucleotide binding domain (N, cytoplasmic) via pentosidine AGEs. 2 weeks
of insulin treatment initiated after 6 weeks of diabetes significantly improved the cardiac function and also prevented the
formation of crosslinking AGEs on SERCA2a. It is suggested
that the disruption in the tertiary structure by AGE complexes prevented the structural movements required for
translocating Ca2+ from the cytosol to the lumen of the SR
and resulted in a decrease in the SERCA2a activity [75].
Other studies have identiﬁed carbonylation and OGlcNAcylation as important mechanisms that contribute to
the loss of the SERCA2a activity and diastolic dysfunction
in a rat model of TIDM [46, 105].

7. Targeting Ca2+ Handling in Diabetes
Taken together, studies strongly suggest that several facets
related to Ca2+ handling are dysregulated in diabetic cardio-
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myopathy, including altered expression and/or activity levels
of the L-type Ca2+ channel activity, RyR2, SERCA2a, and
NCX. Therefore, targeting these proteins provide potential
therapeutic approaches to improve cardiac cell function in
diabetes. Many studies have shown that the L-type Ca2+
channel activity is either unaltered or reduced in diabetes.
The diminished Ca2+ entry through the L-type Ca2+ channel
is a critical contributor to the negative eﬀect on cardiac contractility observed in diabetic cardiomyopathy, and therefore,
an increase of the trigger produced by the L-type Ca2+ current will increase the amplitude of Ca2+ transients and contraction. Gain-of-function mutations in the channel’s α1subunit or other proteins favoring cellular depolarization
might be beneﬁcial in diabetic cardiomyopathy. For example,
mutations that increase the window current and maximal
conductance for Ca2+ will augment the trigger for RyR2mediated Ca2+ release, thereby improving the systolic function in the diabetic heart. Although the increased Ca2+ entry
into the myocytes substantially contributes to the positive
inotropic eﬀect, it is worth noting that excess Ca2+ inﬂux
through the L-type Ca2+ channel is likely to contribute to
intracellular Ca2+ overload.
The NCX function is also reduced according to many
diabetic models. In fact, inhibition of NCX in the forward
mode will further increase the cellular Ca2+ content. This
could be an advantage in conditions of low inotropy but
could also lead to relaxation abnormalities and adverse accumulation of Ca2+ in cytosol and cell death [106]. On the contrary, the inhibition of NCX in the reverse mode could be of
pharmacological importance in limiting the cellular Ca2+
content and Ca2+ overload in ventricular cardiomyocytes
where the NCX activity is increased.
It is evident that remodeling the activity of SERCA2a and
RyR2 favors the improvement of Ca2+ handling in diabetes.
Majority of studies in both models of diabetes have shown
that the activity of RyR2 is increased, while the activity of
SERCA2a is diminished in diabetic ventricular cardiomyocytes. Suppressing RyR2-mediated SR Ca2+ leak by directly
modifying RyR2 gating represents an eﬀective strategy for
preventing spontaneous Ca2+ waves. In this regard, several
drugs with unique inhibitory action on Ca2+ waves have been
tested in earlier studies [107, 108]. These drugs have been
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shown to possess antiarrhythmic eﬀects and could probably
have cardioprotective properties. However, their mechanisms of action are both complex and controversial. Modulation of the RyR2 activity can also be achieved by targeting
CaMK II, which inhibits RyR2 phosphorylation and results
in an overall decreased SR Ca2+ overload [109].
Although the role of RyR2 in excitation-contraction coupling in cardiomyocytes is well established, a functional role
for RyR2 in β cell insulin secretion is not well understood.
Missense mutations in RYR2 were shown to be associated
with catecholaminergic polymorphic ventricular tachycardia
(CPVT), which is characterized by exercise-induced arrhythmias and sudden cardiac death. CPVT patients were found to
have leaky RyR2, present with glucose intolerance. In mice,
the transgenic expression of CPVT-associated RyR2 resulted
in impaired glucose homeostasis. Furthermore, β cells from
these animals revealed intracellular Ca2+ leak via oxidized
and nitrosylated RyR2 channels [110]. It is important to
mention that chronic intracellular Ca2+ leak via RyR2 channels in the pancreatic β cell causes store depletion, triggers
ER stress, and results in mitochondrial dysfunction. Consequently, these eﬀects lead to the reduction in ATP synthesis
and eventually decreased glucose-stimulated insulin secretion by β cells. Impaired mitochondrial function also leads
to increased production of ROS, which triggers redox modiﬁcations of RyR2, thereby aggravating the Ca2+ leak [111].
Therefore, pharmacological inhibition of intracellular Ca2+
leak via RyR2 channels in diabetic patients would be critically
important.
Many studies in both models of diabetes have shown that
the activity of SERCA2a is diminished in diabetic ventricular
cardiomyocytes. Therefore, remodeling the activity of SERCA2a would play an important role in improving the process
of Ca2+ handling in diabetes. The overexpression of SERCA2a and modulation of the inhibitory action of the regulatory protein PLB provide potentially important therapeutic
approaches in improving ventricular contractile function in
diabetes [12]; however, such approaches will need further
extensive studies and testing in relevant animal and preclinical models.
It is worth mentioning that the levels of SERCA can be
assayed in peripheral blood lymphocytes, and their levels
correlate with SERCA levels obtained in the cardiac tissue
[112]. Mechanistically, the decreased SERCA activity results
in Ca2+ overload in the cytoplasm which is known to be
arrhythmogenic. For this reason, assay of SERCA levels could
provide valuable information on proarrhythmogenesis. This
aspect might help clinicians to identify patients with higher
rate of arrhythmic events and worse prognosis. Additionally,
SERCA may become a therapeutic target of tailored therapies
and interventional approaches to reduce the arrhythmic burden in patients. A recent study was conducted to evaluate
atrial ﬁbrillation (AF) recurrence and SERCA levels in
patients treated by epicardial thoracoscopic ablation for persistent AF [113]. After a successful epicardial ablation procedure, there was signiﬁcant increase in the SERCA expression
in responders compared to baseline and to nonresponders.
Responders also displayed a marked reduction of inﬂammatory cytokines. The ﬁndings of this study indicated that
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SERCA may represent an eﬀective therapeutic target to
reduce postablative recurrences in patients with persistent
AF.

8. Conclusion
Over the last decade, signiﬁcant progress has been made in
outlining the mechanisms responsible for the altered cardiac
contractile function in diabetes using diﬀerent animal models
of TIDM and TIIDM. Exploring the molecular mechanism(s) involved in the disturbances of Ca2+ transport and
the role of main cardiac proteins responsible for Ca2+
homeostasis in the diabetic rat ventricular cardiomyocytes
will provide an insight for the identiﬁcation of novel therapeutic approaches to improve heart function in diabetic
patients.

Conflicts of Interest
The author declares that there is no competing interest
regarding the publication of this review.

References
[1] J. M. Forbes and M. E. Cooper, “Mechanisms of diabetic
complications,” Physiological Reviews, vol. 93, no. 1,
pp. 137–188, 2013.
[2] K. R. Bidasee, K. Nallani, Y. Yu et al., “Chronic diabetes
increases advanced glycation end products on cardiac ryanodine receptors/calcium-release channels,” Diabetes, vol. 52,
no. 7, pp. 1825–1836, 2003.
[3] D. K. Patel, R. Kumar, D. Laloo, and S. Hemalatha, “Diabetes
mellitus: an overview on its pharmacological aspects and
reported medicinal plants having antidiabetic activity,” Asian
Paciﬁc Journal of Tropical Biomedicine, vol. 2, no. 5, pp. 411–
420, 2012.
[4] S. Sekhon-Loodu and H. P. V. Rupasinghe, “Evaluation of
antioxidant, Antidiabetic and Antiobesity Potential of
Selected Traditional Medicinal Plants,” Frontiers in Nutrition, vol. 6, p. 53, 2019.
[5] H. Choudhury, M. Pandey, C. K. Hua et al., “An update on
natural compounds in the remedy of diabetes mellitus: a systematic review,” Journal of Traditional and Complementary
Medicine, vol. 8, no. 3, pp. 361–376, 2018.
[6] D. A. Eisner, J. L. Caldwell, K. Kistamás, and A. W. Traﬀord,
“Calcium and excitation-contraction coupling in the heart,”
Circulation Research, vol. 121, no. 2, pp. 181–195, 2017.
[7] I. Bodi, G. Mikala, S. E. Koch, S. A. Akhter, and A. Schwartz,
“The L-type calcium channel in the heart: the beat goes on,”
The Journal of Clinical Investigation, vol. 115, no. 12,
pp. 3306–3317, 2005.
[8] F. Brette, J. Leroy, J. Y. le Guennec, and L. Sallé, “Ca2+ currents in cardiac myocytes: old story, new insights,” Progress
in Biophysics and Molecular Biology, vol. 91, no. 1-2, pp. 1–
82, 2006.
[9] D. M. Bers, “Cardiac excitation-contraction coupling,”
Nature, vol. 415, no. 6868, pp. 198–205, 2002.
[10] C. Walsh, S. Barrow, S. Voronina, M. Chvanov, O. H. Petersen, and A. Tepikin, “Modulation of calcium signalling by
mitochondria,” Biochimica et Biophysica Acta, vol. 1787,
no. 11, pp. 1374–1382, 2009.

Journal of Diabetes Research
[11] R. M. Shaw and H. M. Colecraft, “L-type calcium channel targeting and local signalling in cardiac myocytes,” Cardiovascular Research, vol. 98, no. 2, pp. 177–186, 2013.
[12] S. Hamilton and D. Terentyev, “Proarrhythmic remodeling of
calcium homeostasis in cardiac disease; Implications for Diabetes and Obesity,” Frontiers in Physiology, vol. 9, article
1517, 2018.
[13] J. S. Rougier and H. Abriel, “Cardiac voltage-gated calcium
channel macromolecular complexes,” Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, vol. 1863, no. 7,
pp. 1806–1812, 2016.
[14] A. Y. H. Woo and R. P. Xiao, “β-Adrenergic receptor subtype
signaling in heart: from bench to bedside,” Acta Pharmacologica Sinica, vol. 33, no. 3, pp. 335–341, 2012.
[15] D. T. Yue, S. Herzig, and E. Marban, “Beta-adrenergic stimulation of calcium channels occurs by potentiation of highactivity gating modes,” Proceedings of the National Academy
of Sciences of the United States of America, vol. 87, no. 2,
pp. 753–757, 1990.
[16] B. Z. Peterson, C. DeMaria, J. P. Adelman, and D. T. Yue,
“Calmodulin is the Ca2+ sensor for Ca2+ -dependent inactivation of L-type calcium channels,” Neuron, vol. 22, no. 3,
pp. 549–558, 1999.
[17] R. Bansal, N. Ahmad, and J. R. Kidwai, “Alloxan-glucose
interaction: eﬀect on incorporation of 14C-leucine into pancreatic islets of rat,” Acta Diabetologica Latina, vol. 17,
no. 2, pp. 135–143, 1980.
[18] C. E. Mathews, S. H. Langley, and E. H. Leiter, “New mouse
model to study islet transplantation in insulin-dependent diabetes mellitus,” Transplantation, vol. 73, no. 8, pp. 1333–
1336, 2002.
[19] M. M. A. Smail, M. A. Qureshi, A. Shmygol et al., “Regional
eﬀects of streptozotocin-induced diabetes on shortening
and calcium transport in epicardial and endocardial myocytes from rat left ventricle,” Physiological Reports, vol. 4,
no. 22, article e13034, 2016.
[20] V. A. Lacombe, S. Viatchenko-Karpinski, D. Terentyev et al.,
“Mechanisms of impaired calcium handling underlying subclinical diastolic dysfunction in diabetes,” American Journal
of Physiology. Regulatory, Integrative and Comparative Physiology, vol. 293, no. 5, pp. R1787–R1797, 2007.
[21] K. M. Choi, Y. Zhong, B. D. Hoit et al., “Defective intracellular Ca(2+) signaling contributes to cardiomyopathy
in type 1 diabetic rats,” American Journal of Physiology.
Heart and Circulatory Physiology, vol. 283, no. 4,
pp. H1398–H1408, 2002.
[22] Y. Teshima, N. Takahashi, T. Saikawa et al., “Diminished
expression of sarcoplasmic reticulum Ca(2+)-ATPase and
ryanodine
sensitive
Ca(2+)channel
mRNA
in
streptozotocin-induced diabetic rat heart,” Journal of Molecular and Cellular Cardiology, vol. 32, no. 4, pp. 655–664,
2000.
[23] N. N. Hamouda, V. Sydorenko, M. A. Qureshi, J. M. Alkaabi,
M. Oz, and F. C. Howarth, “Dapagliﬂozin reduces the amplitude of shortening and Ca(2+) transient in ventricular myocytes from streptozotocin-induced diabetic rats,” Molecular
and Cellular Biochemistry, vol. 400, no. 1-2, pp. 57–68, 2015.
[24] D. W. Wang, T. Kiyosue, S. Shigematsu, and M. Arita,
“Abnormalities of K+ and Ca2+ currents in ventricular myocytes from rats with chronic diabetes,” The American Journal
of Physiology, vol. 269, 4 Part 2, pp. H1288–H1296, 1995.

9
[25] A. Woodall, N. Bracken, A. Qureshi, F. C. Howarth, and
J. Singh, “Halothane alters contractility and Ca2+ transport
in ventricular myocytes from streptozotocin-induced diabetic
rats,” Molecular and Cellular Biochemistry, vol. 261, no. 1,
pp. 251–261, 2004.
[26] S. Chattou, J. Diacono, and D. Feuvray, “Decrease in sodiumcalcium exchange and calcium currents in diabetic rat ventricular myocytes,” Acta Physiologica Scandinavica, vol. 166,
no. 2, pp. 137–144, 1999.
[27] Z. Lu, Y. P. Jiang, X. H. Xu, L. M. Ballou, I. S. Cohen, and R. Z.
Lin, “Decreased L-type Ca2+ current in cardiac myocytes of
type 1 diabetic Akita mice due to reduced phosphatidylinositol 3-kinase signaling,” Diabetes, vol. 56,
no. 11, pp. 2780–2789, 2007.
[28] N. Bracken, F. C. Howarth, and J. Singh, “Eﬀects of
streptozotocin-induced diabetes on contraction and calcium
transport in rat ventricular cardiomyocytes,” Annals of the
New York Academy of Sciences, vol. 1084, no. 1, pp. 208–
222, 2006.
[29] L. Pereira, J. Matthes, I. Schuster et al., “Mechanisms of
[Ca2+]i transient decrease in cardiomyopathy of db/db type
2 diabetic mice,” Diabetes, vol. 55, no. 3, pp. 608–615, 2006.
[30] T. O. Stølen, M. A. Høydal, O. J. Kemi et al., “Interval training
normalizes cardiomyocyte function, diastolic Ca2+ control,
and SR Ca2+ release synchronicity in a mouse model of diabetic cardiomyopathy,” Circulation Research, vol. 105, no. 6,
pp. 527–536, 2009.
[31] F. C. Howarth, M. A. Qureshi, Z. Hassan et al., “Changing
pattern of gene expression is associated with ventricular myocyte dysfunction and altered mechanisms of Ca2+ signalling
in young type 2 Zucker diabetic fatty rat heart,” Experimental
Physiology, vol. 96, no. 3, pp. 325–337, 2011.
[32] K. A. Salem, M. A. Qureshi, V. Sydorenko et al., “Eﬀects of
exercise training on excitation-contraction coupling and
related mRNA expression in hearts of Goto-Kakizaki type 2
diabetic rats,” Molecular and Cellular Biochemistry, vol. 380,
no. 1-2, pp. 83–96, 2013.
[33] L. Al Kury, V. Sydorenko, M. M. A. Smail et al., “Voltage
dependence of the Ca2+ transient in endocardial and epicardial myocytes from the left ventricle of Goto-Kakizaki type 2
diabetic rats,” Molecular and Cellular Biochemistry, vol. 446,
no. 1-2, pp. 25–33, 2018.
[34] D. Baddeley, I. D. Jayasinghe, L. Lam, S. Rossberger, M. B.
Cannell, and C. Soeller, “Optical single-channel resolution
imaging of the ryanodine receptor distribution in rat cardiac
myocytes,” Proceedings of the National Academy of Sciences of
the United States of America, vol. 106, no. 52, pp. 22275–
22280, 2009.
[35] H. Cheng, M. R. Lederer, W. J. Lederer, and M. B. Cannell,
“Calcium sparks and [Ca2+]i waves in cardiac myocytes,”
American Journal of Physiology-Cell Physiology, vol. 270,
no. 1, pp. C148–C159, 1996.
[36] Y. Hou, I. Jayasinghe, D. J. Crossman, D. Baddeley, and
C. Soeller, “Nanoscale analysis of ryanodine receptor clusters
in dyadic couplings of rat cardiac myocytes,” Journal of
Molecular and Cellular Cardiology, vol. 80, pp. 45–55, 2015.
[37] I. Györke, N. Hester, L. R. Jones, and S. Györke, “The role of
calsequestrin, triadin, and junctin in conferring cardiac ryanodine receptor responsiveness to luminal calcium,” Biophysical Journal, vol. 86, no. 4, pp. 2121–2128, 2004.
[38] S. Györke and D. Terentyev, “Modulation of ryanodine
receptor by luminal calcium and accessory proteins in health

10

[39]

[40]

[41]

[42]

[43]

[44]

[45]

[46]

[47]

[48]

[49]

[50]

[51]

[52]

Journal of Diabetes Research
and cardiac disease,” Cardiovascular Research, vol. 77, no. 2,
pp. 245–255, 2008.
D. M. Bers, “Macromolecular complexes regulating cardiac
ryanodine receptor function,” Journal of Molecular and Cellular Cardiology, vol. 37, no. 2, pp. 417–429, 2004.
L. A. Gonano and P. P. Jones, “FK506-binding proteins 12
and 12.6 (FKBPs) as regulators of cardiac ryanodine receptors: insights from new functional and structural knowledge,”
Channels, vol. 11, no. 5, pp. 415–425, 2017.
E. Niggli, N. D. Ullrich, D. Gutierrez, S. Kyrychenko,
E. Poláková, and N. Shirokova, “Posttranslational modiﬁcations of cardiac ryanodine receptors: Ca(2+) signaling and
EC-coupling,” Biochimica et Biophysica Acta, vol. 1833,
no. 4, pp. 866–875, 2013.
D. Terentyev and S. Hamilton, “Regulation of sarcoplasmic
reticulum Ca2+ release by serine-threonine phosphatases in
the heart,” Journal of Molecular and Cellular Cardiology,
vol. 101, pp. 156–164, 2016.
J. Hain, H. Onoue, M. Mayrleitner, S. Fleischer, and
H. Schindler, “Phosphorylation modulates the function of
the calcium release channel of sarcoplasmic reticulum from
cardiac muscle,” The Journal of Biological Chemistry,
vol. 270, no. 5, pp. 2074–2081, 1995.
K. R. Eager, L. D. Roden, and A. F. Dulhunty, “Actions of
sulfhydryl reagents on single ryanodine receptor Ca(2+)release channels from sheep myocardium,” American Journal
of Physiology–Cell Physiology, vol. 272, no. 6, pp. C1908–
C1918, 1997.
L. Xu, J. P. Eu, G. Meissner, and J. S. Stamler, “Activation of
the cardiac calcium release channel (ryanodine receptor) by
poly-S-nitrosylation,” Science, vol. 279, no. 5348, pp. 234–
237, 1998.
C. H. Shao, C. Tian, S. Ouyang et al., “Carbonylation induces
heterogeneity in cardiac ryanodine receptor function in diabetes mellitus,” Molecular Pharmacology, vol. 82, no. 3,
pp. 383–399, 2012.
L. S. Song, E. A. Sobie, S. McCulle, W. J. Lederer, C. W. Balke,
and H. Cheng, “Orphaned ryanodine receptors in the failing
heart,” Proceedings of the National Academy of Sciences of the
United States of America, vol. 103, no. 11, pp. 4305–4310,
2006.
Z. Yu, G. F. Tibbits, and J. H. McNeill, “Cellular functions of
diabetic cardiomyocytes: contractility, rapid-cooling contracture, and ryanodine binding,” American Journal of
Physiology-Heart and Circulatory Physiology, vol. 266, no. 5,
pp. H2082–H2089, 1994.
S.-M. Zhao, Y. L. Wang, C. Y. Guo, J. L. Chen, and Y. Q. Wu,
“Progressive decay of Ca2+ homeostasis in the development
of diabetic cardiomyopathy,” Cardiovascular Diabetology,
vol. 13, no. 1, pp. 75–75, 2014.
G. E. Gilca, G. Stefanescu, O. Badulescu, D. M. Tanase,
I. Bararu, and M. Ciocoiu, “Diabetic cardiomyopathy: current
approach and potential diagnostic and therapeutic targets,”
Journal Diabetes Research, vol. 2017, article 1310265, 7 pages,
2017.
C.-H. Shao, X. H. T. Wehrens, T. A. Wyatt et al., “Exercise
training during diabetes attenuates cardiac ryanodine receptor dysregulation,” Journal of Applied Physiology, vol. 106,
no. 4, pp. 1280–1292, 2009.
N. Yaras, M. Ugur, S. Ozdemir et al., “Eﬀects of diabetes on
ryanodine receptor Ca release channel (RyR2) and Ca2+

[53]

[54]

[55]

[56]

[57]

[58]

[59]

[60]

[61]

[62]

[63]

[64]

[65]

[66]

homeostasis in rat heart,” Diabetes, vol. 54, no. 11,
pp. 3082–3088, 2005.
E. Tuncay, E. N. Okatan, A. Toy, and B. Turan, “Enhancement of cellular antioxidant-defence preserves diastolic dysfunction via regulation of both diastolic Zn2+ and Ca2+
and prevention of RyR2-leak in hyperglycemic cardiomyocytes,” Oxidative Medicine and Cellular Longevity, vol. 2014,
Article ID 290381, 15 pages, 2014.
C. H. Shao, G. J. Rozanski, K. P. Patel, and K. R. Bidasee,
“Dyssynchronous (non-uniform) Ca2+ release in myocytes
from streptozotocin-induced diabetic rats,” Journal of Molecular and Cellular Cardiology, vol. 42, no. 1, pp. 234–246,
2007.
X. H. Wehrens, S. E. Lehnart, S. R. Reiken, and A. R. Marks,
“Ca2+/calmodulin-dependent protein kinase II phosphorylation regulates the cardiac ryanodine receptor,” Circulation
Research, vol. 94, no. 6, pp. e61–e70, 2004.
D. R. Witcher, R. J. Kovacs, H. Schulman, D. C. Cefali, and
L. R. Jones, “Unique phosphorylation site on the cardiac ryanodine receptor regulates calcium channel activity,” The
Journal of Biological Chemistry, vol. 266, no. 17, pp. 11144–
11152, 1991.
S. Huke and D. M. Bers, “Ryanodine receptor phosphorylation at serine 2030, 2808 and 2814 in rat cardiomyocytes,”
Biochemical and Biophysical Research Communications,
vol. 376, no. 1, pp. 80–85, 2008.
S. O. Marx, S. Reiken, Y. Hisamatsu et al., “PKA phosphorylation dissociates FKBP12.6 from the calcium release channel
(ryanodine receptor): defective regulation in failing hearts,”
Cell, vol. 101, no. 4, pp. 365–376, 2000.
T. Netticadan, R. M. Temsah, A. Kent, V. Elimban, and N. S.
Dhalla, “Depressed levels of Ca2+-cycling proteins may
underlie sarcoplasmic reticulum dysfunction in the diabetic
heart,” Diabetes, vol. 50, no. 9, pp. 2133–2138, 2001.
C. Tian, C. Hong Shao, C. J. Moore et al., “Gain of function of
cardiac ryanodine receptor in a rat model of type 1 diabetes,”
Cardiovascular Research, vol. 91, no. 2, pp. 300–309, 2011.
U. D. Dincer, A. Araiza, J. D. Knudson, C. H. Shao, K. R.
Bidasee, and J. D. Tune, “Dysfunction of cardiac ryanodine
receptors in the metabolic syndrome,” Journal of Molecular
and Cellular Cardiology, vol. 41, no. 1, pp. 108–114, 2006.
E. N. Okatan, A. T. Durak, and B. Turan, “Electrophysiological basis of metabolic-syndrome-induced cardiac dysfunction,” Canadian Journal of Physiology and Pharmacology,
vol. 94, no. 10, pp. 1064–1073, 2016.
E. M. Gaber, P. Jayaprakash, M. A. Qureshi et al., “Eﬀects of a
sucrose-enriched diet on the pattern of gene expression, contraction and Ca2+transport in Goto-Kakizaki type 2 diabetic rat
heart,” Experimental Physiology, vol. 99, no. 6, pp. 881–893, 2014.
H. Reuter, S. Grönke, C. Adam et al., “Sarcoplasmic Ca2+
release is prolonged in nonfailing myocardium of diabetic
patients,” Molecular and Cellular Biochemistry, vol. 308,
no. 1-2, pp. 141–149, 2008.
L. C. Joseph, P. Subramanyam, C. Radlicz et al., “Mitochondrial oxidative stress during cardiac lipid overload causes
intracellular calcium leak and arrhythmia,” Heart Rhythm,
vol. 13, no. 8, pp. 1699–1706, 2016.
Y. Xie, Z. J. Gu, M. X. Wu et al., “Disruption of calcium
homeostasis by cardiac-speciﬁc over-expression of PPAR-γ
in mice: a role in ventricular arrhythmia,” Life Sciences,
vol. 167, pp. 12–21, 2016.

Journal of Diabetes Research
[67] T. Oda, Y. Yang, H. Uchinoumi et al., “Oxidation of ryanodine receptor (RyR) and calmodulin enhance Ca release and
pathologically alter, RyR structure and calmodulin aﬃnity,”
Journal of Molecular and Cellular Cardiology, vol. 85,
pp. 240–248, 2015.
[68] D. R. Gonzalez, F. Beigi, A. V. Treuer, and J. M. Hare, “Deﬁcient ryanodine receptor S-nitrosylation increases sarcoplasmic reticulum calcium leak and arrhythmogenesis in
cardiomyocytes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 51,
pp. 20612–20617, 2007.
[69] G. Sánchez, F. Araneda, J. Peña et al., “High-fat-diet-induced
obesity produces spontaneous ventricular arrhythmias and
increases the activity of ryanodine receptors in mice,” International Journal of Molecular Sciences, vol. 19, no. 2, p. 533,
2018.
[70] M. Periasamy and A. Kalyanasundaram, “SERCA pump isoforms: their role in calcium transport and disease,” Muscle &
Nerve, vol. 35, no. 4, pp. 430–442, 2007.
[71] K. F. Frank, B. Bölck, E. Erdmann, and R. H. Schwinger, “Sarcoplasmic reticulum Ca2+-ATPase modulates cardiac contraction and relaxation,” Cardiovascular Research, vol. 57,
no. 1, pp. 20–27, 2003.
[72] T. Toyofuku, K. Curotto Kurzydlowski, N. Narayanan, and
D. MacLennan, “Identiﬁcation of Ser38 as the site in cardiac
sarcoplasmic reticulum Ca(2+)-ATPase that is phosphorylated by Ca2+/calmodulin-dependent protein kinase,” The
Journal of Biological Chemistry, vol. 269, no. 42, pp. 26492–
26496, 1994.
[73] P. K. Ganguly, G. N. Pierce, K. S. Dhalla, and N. S. Dhalla,
“Defective sarcoplasmic reticular calcium transport in diabetic cardiomyopathy,” The American Journal of Physiology,
vol. 244, no. 6, pp. E528–E535, 1983.
[74] H. W. Kim, Y. S. Cho, H. R. Lee, S. Y. Park, and Y. H. Kim,
“Diabetic alterations in cardiac sarcoplasmic reticulum
Ca2+-ATPase and phospholamban protein expression,” Life
Sciences, vol. 70, no. 4, pp. 367–379, 2001.
[75] K. R. Bidasee, Y. Zhang, C. H. Shao et al., “Diabetes increases
formation of advanced glycation end products on Sarco(endo)plasmic reticulum Ca2+-ATPase,” Diabetes, vol. 53,
no. 2, pp. 463–473, 2004.
[76] G. D. Lopaschuk, S. Katz, and J. H. McNeill, “The eﬀect of
alloxan- and streptozotocin-induced diabetes on calcium
transport in rat cardiac sarcoplasmic reticulum. The possible
involvement of long chain acylcarnitines,” Canadian Journal
of Physiology and Pharmacology, vol. 61, no. 5, pp. 439–448,
1983.
[77] S. N. Allo, T. M. Lincoln, G. L. Wilson, F. J. Green, A. M.
Watanabe, and S. W. Schaﬀer, “Non-insulin-dependent
diabetes-induced defects in cardiac cellular calcium regulation,” American Journal of Physiology-Cell Physiology,
vol. 260, no. 6, pp. C1165–C1171, 1991.
[78] E. Okabe, M. L. Hess, M. Oyama, and H. Ito, “Characterization of free radical-mediated damage of canine cardiac sarcoplasmic reticulum,” Archives of Biochemistry and Biophysics,
vol. 225, no. 1, pp. 164–177, 1983.
[79] K. Y. Xu, J. L. Zweier, and L. C. Becker, “Hydroxyl radical
inhibits sarcoplasmic reticulum Ca(2+)-ATPase function by
direct attack on the ATP binding site,” Circulation Research,
vol. 80, no. 1, pp. 76–81, 1997.
[80] J. Ying, V. Sharov, S. Xu et al., “Cysteine-674 oxidation and
degradation of sarcoplasmic reticulum Ca(2+) ATPase in

11

[81]

[82]

[83]

[84]

[85]

[86]

[87]

[88]

[89]

[90]

[91]

[92]

[93]

[94]

[95]

diabetic pig aorta,” Free Radical Biology & Medicine, vol. 45,
no. 6, pp. 756–762, 2008.
L. E. Wold, K. Dutta, M. M. Mason et al., “Impaired SERCA
function contributes to cardiomyocyte dysfunction in insulin
resistant rats,” Journal of Molecular and Cellular Cardiology,
vol. 39, no. 2, pp. 297–307, 2005.
M. E. Young, P. H. Guthrie, P. Razeghi et al., “Impaired longchain fatty acid oxidation and contractile dysfunction in the
obese Zucker rat heart,” Diabetes, vol. 51, no. 8, pp. 2587–
2595, 2002.
S. Fredersdorf, C. Thumann, W. H. Zimmermann et al.,
“Increased myocardial SERCA expression in early type 2 diabetes mellitus is insulin dependent: in vivo and in vitro data,”
Cardiovascular Diabetology, vol. 11, no. 1, pp. 57–57, 2012.
A. Herchuelz and N. Pachera, “The Na + /Ca 2+ exchanger
and the plasma membrane Ca 2+ -ATPase in β-cell function
and diabetes,” Neuroscience Letters, vol. 663, pp. 72–78, 2018.
M. J. Shattock, M. Ottolia, D. M. Bers et al., “Na+/Ca2+
exchange and Na+/K+-ATPase in the heart,” The Journal of
Physiology, vol. 593, no. 6, pp. 1361–1382, 2015.
M. J. Riedel, I. Baczkó, G. J. Searle et al., “Metabolic regulation
of sodium-calcium exchange by intracellular acyl CoAs,” The
EMBO Journal, vol. 25, no. 19, pp. 4605–4614, 2006.
M. Ottolia, N. Torres, J. H. B. Bridge, K. D. Philipson, and J. I.
Goldhaber, “Na/Ca exchange and contraction of the heart,”
Journal of Molecular and Cellular Cardiology, vol. 61,
pp. 28–33, 2013.
M. Reppel, B. Fleischmann, H. Reuter, P. Sasse, H. Schunkert,
and J. Hescheler, “Regulation of the Na+/Ca2+ exchanger
(NCX) in the murine embryonic heart,” Cardiovascular
Research, vol. 75, no. 1, pp. 99–108, 2007.
S. Wagner, T. Seidler, E. Picht et al., “Na(+)-Ca(2+)
exchanger overexpression predisposes to reactive oxygen
species-induced injury,” Cardiovascular Research, vol. 60,
no. 2, pp. 404–412, 2003.
Y. Hattori, N. Matsuda, J. Kimura et al., “Diminished function and expression of the cardiac Na+-Ca2+ exchanger in
diabetic rats: implication in Ca2+ overload,” The Journal of
Physiology, vol. 527, no. 1, pp. 85–94, 2000.
A. Q. Sheikh, J. R. Hurley, W. Huang et al., “Diabetes alters
intracellular calcium transients in cardiac endothelial cells,”
PLoS One, vol. 7, no. 5, article e36840, 2012.
T. I. Lee, Y. C. Chen, Y. H. Kao, F. C. Hsiao, Y. K. Lin, and
Y. J. Chen, “Rosiglitazone induces arrhythmogenesis in diabetic hypertensive rats with calcium handling alteration,”
International Journal of Cardiology, vol. 165, no. 2, pp. 299–
307, 2013.
L. Zhang, M. L. Ward, A. R. J. Phillips et al., “Protection of the
heart by treatment with a divalent-copper-selective chelator
reveals a novel mechanism underlying cardiomyopathy in diabetic rats,” Cardiovascular Diabetology, vol. 12, no. 1, p. 123, 2013.
L. Golfman, I. M. C. Dixon, N. Takeda, A. Lukas,
K. Dakshinamurti, and N. S. Dhalla, “Cardiac sarcolemmal
Na(+)-Ca2+ exchange and Na(+)-K+ ATPase activities and
gene expression in alloxan-induced diabetes in rats,” Molecular and Cellular Biochemistry, vol. 188, no. 1/2, pp. 91–101,
1998.
L. T. Al Kury, V. Sydorenko, M. M. A. Smail et al., “Calcium
Signaling in Endocardial and Epicardial Ventricular Myocytes from Streptozotocin‐Induced Diabetic Rat,” Journal of
Diabetes Investigation, 2020.

12
[96] T. J. LaRocca, F. Fabris, J. Chen et al., “Na+/Ca2+exchanger-1
protects against systolic failure in the Akitains2model of diabetic cardiomyopathy via a CXCR4/NF-κB pathway,” American Journal of Physiology. Heart and Circulatory Physiology,
vol. 303, no. 3, pp. H353–H367, 2012.
[97] E. Ricci, S. Smallwood, C. Chouabe et al., “Electrophysiological characterization of left ventricular myocytes from obese
Sprague-Dawley rat,” Obesity (Silver Spring), vol. 14, no. 5,
pp. 778–786, 2006.
[98] R. Ashraﬁ, P. Modi, A. Y. Oo et al., “Arrhythmogenic gene
remodelling in elderly patients with type 2 diabetes with aortic stenosis and normal left ventricular ejection fraction,”
Experimental Physiology, vol. 102, no. 11, pp. 1424–1434,
2017.
[99] Z. Hegab, S. Gibbons, L. Neyses, and M. A. Mamas, “Role of
advanced glycation end products in cardiovascular disease,”
World Journal of Cardiology, vol. 4, no. 4, pp. 90–102, 2012.
[100] Z. Hegab, T. M. A. Mohamed, N. Staﬀord, M. Mamas, E. J.
Cartwright, and D. Oceandy, “Advanced glycation end products reduce the calcium transient in cardiomyocytes by
increasing production of reactive oxygen species and nitric
oxide,” FEBS Open Bio, vol. 7, no. 11, pp. 1672–1685, 2017.
[101] D. Yan, X. Luo, Y. Li et al., “Eﬀects of advanced glycation end
products on calcium handling in cardiomyocytes,” Cardiology, vol. 129, no. 2, pp. 75–83, 2014.
[102] M. Poteser, C. Romanin, W. Schreibmayer, B. Mayer, and
K. Groschner, “S-nitrosation controls gating and conductance of the α1 subunit of class C L-type Ca2+Channels,”
The Journal of Biological Chemistry, vol. 276, no. 18,
pp. 14797–14803, 2001.
[103] K. R. Bidasee, K. Nallani, H. R. Besch Jr., and U. D. Dincer,
“Streptozotocin-induced diabetes increases disulﬁde bond
formation on cardiac ryanodine receptor (RyR2),” The Journal of Pharmacology and Experimental Therapeutics,
vol. 305, no. 3, pp. 989–998, 2003.
[104] M. Ruiz-Meana, M. Minguet, D. Bou-Teen et al., “Ryanodine
receptor glycation favors mitochondrial damage in the senescent heart,” Circulation, vol. 139, no. 7, pp. 949–964, 2019.
[105] Y. Hu, D. Belke, J. Suarez et al., “Adenovirus-mediated overexpression of O-GlcNAcase improves contractile function in
the diabetic heart,” Circulation Research, vol. 96, no. 9,
pp. 1006–1013, 2005.
[106] G. Antoons, R. Willems, and K. R. Sipido, “Alternative strategies in arrhythmia therapy: evaluation of Na/Ca exchange as
an anti-arrhythmic target,” Pharmacology & Therapeutics,
vol. 134, no. 1, pp. 26–42, 2012.
[107] J. Zhang, Q. Zhou, C. D. Smith et al., “Non-β-blocking Rcarvedilol enantiomer suppresses Ca2+ waves and stressinduced ventricular tachyarrhythmia without lowering heart
rate or blood pressure,” The Biochemical Journal, vol. 470,
no. 2, pp. 233–242, 2015.
[108] D. J. Hunt, P. P. Jones, R. Wang et al., “K201 (JTV519) suppresses spontaneous Ca2+ release and [3H]ryanodine binding to RyR2 irrespective of FKBP12.6 association,” The
Biochemical Journal, vol. 404, no. 3, pp. 431–438, 2007.
[109] H. Uchinoumi, Y. Yang, T. Oda et al., “CaMKII-dependent
phosphorylation of RyR2 promotes targetable pathological
RyR2 conformational shift,” Journal of Molecular and Cellular
Cardiology, vol. 98, pp. 62–72, 2016.
[110] G. Santulli, G. Pagano, C. Sardu et al., “Calcium release channel RyR2 regulates insulin release and glucose homeostasis,”

Journal of Diabetes Research
The Journal of Clinical Investigation, vol. 125, no. 5,
pp. 1968–1978, 2015.
[111] C. Tang, K. Koulajian, I. Schuiki et al., “Glucose-induced beta
cell dysfunction in vivo in rats: link between oxidative stress
and endoplasmic reticulum stress,” Diabetologia, vol. 55,
no. 5, pp. 1366–1379, 2012.
[112] J. E. Kontaraki, F. I. Parthenakis, E. G. Nyktari, A. P. Patrianakos, and P. E. Vardas, “Myocardial gene expression alterations in peripheral blood mononuclear cells of patients
with idiopathic dilated cardiomyopathy,” European Journal
of Heart Failure, vol. 12, no. 6, pp. 541–548, 2010.
[113] C. Sardu, G. Santulli, G. Guerra et al., “Modulation of SERCA
in patients with persistent atrial ﬁbrillation treated by epicardial thoracoscopic ablation: the CAMAF study,” Journal of
Clinical Medicine, vol. 9, no. 2, p. 544, 2020.

